Fidasimtamab, designated DLTV – 1504, represents a innovative avenue in the fight against multiple myeloma. The drug is a dual-specific agent designed to concurrently engage CD3-positive lymphocytes https://fidasimtamabibi315172734.blog-gold.com/61134884/fidasimtamab-this-emerging-treatment-in-advanced-blood-management